News Releases

GAITHERSBURG, MD . and SHANGHAI , Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and

GAITHERSBURG, MD . and SHANGHAI, China , Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical

GAITHERSBURG, Md. and SHANGHAI , Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2

Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% Lemzoparlimab does not require priming dosing with

Abstract summarizing lemzoparlimab Phase 2 data selected for proffered paper presentation on September 10 Investor conference call scheduled at 8:00 a.m. ET (English) on September 12 GAITHERSBURG, Md. and SHANGHAI, China , Sept. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a

Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4B Lemzoparlimab is on track for Phase 3 study for 1L MDS Amendment to the global partnership with AbbVie for certain new CD47 antibodies currently in development with up

GAITHERSBURG, Md. and SHANGHAI , Aug. 23, 2022 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share

-  M ajor updates will focus on global clinical development of core assets, upcoming milestones and financial results -  The Company will update on potential implementation of a comprehensive share purchase program by the Company and current shareholders -  Conference Calls Scheduled at 7:00 a.m.

GAITHERSBURG, Md. and SHANGHAI , July 22, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in China has been treated with

GAITHERSBURG, Md. and SHANGHAI , July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data